Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$16.98 USD

16.98
5,678,757

+0.17 (1.01%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $16.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Kinjel Shah headshot

Allergan (AGN) Tops Q4 Earnings; 2017 Sales View Upbeat

Allergan plc's (AGN) fourth-quarter 2016 earnings came in at $3.90 per share, beating the Zacks Consensus Estimate of $3.79 by 2.9%.

    Teva (TEVA) Q4 Earnings: What's in Store for the Stock?

    Teva Pharmaceutical Industries Ltd. (TEVA) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.

      Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO

      Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that its present chief executive officer (CEO), Erez Vigodman, is stepping down.

        Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3

        Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 42 cents, down 16% year over year.

          Allergan (AGN) Q4 Earnings: What's in Store for the Stock?

          Allergan plc (AGN) will be reporting fourth-quarter 2016 earnings on Feb 8, before the market opens. Last quarter, the company delivered a negative earnings surprise of 7.00%.

            Momenta Says District of Delaware Invalidates Teva's MS Drug

            Shares of Momenta Pharmaceuticals, Inc. (MNTA) shot up 25.2% after Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the latter .

              Mylan (MYL) Gets Favorable Verdict for Copaxone in the US

              Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the company pertaining to claims related to Teva Pharmaceutical's (TEVA) Copaxone 40mg/mL.

                Allergan (AGN) Avycaz Label to Include New Phase III Data

                Allergan plc (AGN) announced that its supplemental new drug application (sNDA) for antibiotic Avycaz has been approved by the FDA. Allergan is looking to include new data from two phase III trials, RECAPTURE and REPRISE, in the drug???s label.

                  Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?

                  We expect Eli Lilly and Company (LLY) to beat expectations when it reports fourth-quarter and full-year 2016 earnings results on Jan 31, before market opens.

                    Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval

                    Teva Pharmaceutical Industries Ltd. (TEVA) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment.

                      Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout

                      Eli Lilly and Company (LLY) announced that it plans to buy Cambridge, MA-based biotech firm CoLucid Pharmaceuticals, Inc. (CLCD) for approximately $960 million in cash.

                        Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended

                        Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).

                          Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit

                          Eli Lilly and Company (LLY) announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited (TEVA) related to the infringement of a vitamin regimen patent for its cancer drug Alimta.

                            New Strong Sell Stocks for January 11th

                            Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday

                              Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B

                              Merrimack Pharmaceuticals, Inc. (MACK) announced that it has entered into an agreement with Ipsen for $1.0 billion for Onivyde.

                                Stock Market News for January 09, 2017

                                Benchmarks posted modest gains on Friday following a solid December U.S. jobs report

                                  Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit

                                  Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.

                                    Teva Falls on Disappointing 2017 Sales & Earnings Guidance

                                    Teva Pharmaceutical Industries Ltd. (TEVA) provided a weaker-than-expected sales and earnings guidance for 2017, seeing that its blockbuster multiple sclerosis drug, Copaxone, is reeling under competitive pressures.

                                      Madeleine Johnson headshot

                                      Here's Why Teva Pharmaceuticals is Plunging Today

                                      On Friday, shares of Teva Pharmaceuticals Industries (TEVA) are plunging, down almost 7.7% in late-afternoon trading after the company announced weaker-than-expected 2017 guidance.

                                        Teva Settles Foreign Bribery Charges with U.S. Government

                                        Teva (TEVA) announced that it has completed negotiations with the U.S. government over violations of the Foreign Corrupt Practices Act.

                                          Allergan to Buy LifeCell to Boost Regenerative Medicine Suite

                                          Allergan plc (AGN) announced that it has signed a definitive agreement to acquire LifeCell, the regenerative medicine unit of Texas-based privately held company Acelity for $2.9 billion in cash.

                                            Mylan (MYL) Launches Authorized Generic EpiPen at $300

                                            Mylan (MYL) announced the launch of the first generic version of its life-saving allergy treatment, EpiPen, at more than 50% discount to the branded product.

                                              Arpita Dutt headshot

                                              20 States Sue Teva, Mylan & Other Drug Companies for Price Fixing

                                              The lawsuit and the DoJ antitrust probe pose headline risk for generic companies like Mylan (MYL) and Teva (TEVA).

                                                Arpita Dutt headshot

                                                Generic Stocks Feel Pricing Heat, 1st Charges Filed in DoJ Antitrust Probe

                                                Key generic drugmakers including Teva (TEVA) saw their shares slip on news that the first charges have been filed in the investigation related to generic drug pricing.

                                                  Teva Copaxone EU Label to Omit Pregnancy Contraindication

                                                  Teva Pharmaceutical Industries Ltd. (TEVA) announced that it has received a positive outcome to remove the pregnancy contraindication from the label of its key drug Copaxone in the EU.